We invest where scientific IP, early commercial proof and exceptional founders converge. Fast, respectful diligence. Long-term alignment.
What we offer →Europe’s strongest deeptech opportunities often begin as under-commercialised IP, research-led engineering, specialist technical teams, or narrow wedges into very large industrial markets.
Markovian backs companies at the point where deep technical advantage meets early evidence of market pull. We favour IP-heavy startups with European operations, credible early commercial signals, and a path to global relevance.
Oxford, Cambridge and Munich are Europe’s strength. Markovian exists to compound from those ecosystems.
From lab constraint to scalable platform.
We look for companies turning biology into an engineering discipline: protein synthesis, therapeutics infrastructure, phage platforms, screening systems, and technologies that unlock new drug-development economics.
Software where the buyer is technical and the pain is measurable.
We favour systems that make expert work faster, safer or cheaper: AI tooling, verification, scientific automation, and applied software where the product creates a hard operating advantage rather than cosmetic productivity.
Hard technology, real customers.
We back technical founders commercialising defensible hardware, EDA, semiconductor tooling, robotics, and infrastructure where early customer validation can unlock large markets despite engineering complexity.
Markovian develops internal research on irreversible failure, strategic information design and tail-event modelling — frameworks intended to improve judgement in deep technology systems where rare discontinuities can dominate long-term outcomes.
The work draws from dynamic games, decision theory and systemic risk analysis, with applications spanning AI safety, biosecurity, semiconductor infrastructure, financial fragility and institutional resilience.
“Play long-term games with long-term people. All returns in life come from compound interest in long-term games.”
Capital deployed with a portfolio-wide view.
Markovian’s investment activity is structured around long-horizon ownership, concentrated exposure and compounding rather than fund-cycle pressure.
Small tickets, high conviction, serious networks.
The partnership model is built for co-investment with trusted backers, enabling rapid access to competitive rounds without behaving like a large institutional fund.
A 30-year pathway to permanent endowment formation.
The Markovian foundation concept is designed to convert the majority of long-term venture compounding into a permanent endowment supporting impactful medicine and biotechnology scholarship.